Metabolic profile of antipsychotic-naive individuals with non-affective psychosis
…, T Donner, I Conget, E Parellada… - The British journal of …, 2009 - cambridge.org
BackgroundSome studies suggest individuals with schizophrenia have an increased risk of
diabetes prior to antipsychotic use. Small sample sizes and the potential for confounding by …
diabetes prior to antipsychotic use. Small sample sizes and the potential for confounding by …
Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: report from a worldwide epicentre
…, I Pacchiarotti, M Garriga, A Murru, E Parellada… - Journal of Affective …, 2021 - Elsevier
Background During the COVID-19 pandemic, a structural reorganization was imposed on
public health systems. Psychiatry services were also affected with the imposed reduction of non…
public health systems. Psychiatry services were also affected with the imposed reduction of non…
Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute …
AM Catafau, E Parellada, FJ Lomeña… - Journal of nuclear …, 1994 - europepmc.org
Methods A selected population of 10 young, never-treated schizophrenic women with acute
disease was studied by two hexamethylpropyleneamine oxime (HMPAO) brain SPECT …
disease was studied by two hexamethylpropyleneamine oxime (HMPAO) brain SPECT …
[HTML][HTML] Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
E Parellada, P Gassó - Translational psychiatry, 2021 - nature.com
Schizophrenia disorder remains an unsolved puzzle. However, the integration of recent
findings from genetics, molecular biology, neuroimaging, animal models and translational …
findings from genetics, molecular biology, neuroimaging, animal models and translational …
Clinical, neuroimmunologic, and CSF investigations in first episode psychosis
…, A Saiz, F Graus, J Castro-Fornieles, E Parellada… - Neurology, 2021 - AAN Enterprises
Objectives To report the neuropsychiatric features and frequency of NMDA receptor (NMDAR)
and other neuronal immunoglobulin G antibodies in patients with first episode psychosis (…
and other neuronal immunoglobulin G antibodies in patients with first episode psychosis (…
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
…, SD Martin, R Medori, E Parellada… - International Clinical …, 2005 - journals.lww.com
The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was
investigated in patients with schizophrenia or other psychoses who were transitioned directly from …
investigated in patients with schizophrenia or other psychoses who were transitioned directly from …
Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis
…, C Oliveira, A Justicia, E Parellada… - Schizophrenia …, 2012 - Elsevier
BACKGROUND: Previous studies have found increased prolactin concentrations in
antipsychotic-naïve patients with schizophrenia. However, the roles of other hormones, and of …
antipsychotic-naïve patients with schizophrenia. However, the roles of other hormones, and of …
Glucose abnormalities in the siblings of people with schizophrenia
E Fernandez-Egea, M Bernardo, E Parellada… - Schizophrenia …, 2008 - Elsevier
BACKGROUND: Some studies suggest that schizophrenia may be associated with an
increased risk of diabetes, independently of antipsychotic medications and other confounding …
increased risk of diabetes, independently of antipsychotic medications and other confounding …
Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia
E Parellada, M Bioque - CNS drugs, 2016 - Springer
Schizophrenia and related disorders remain major disabling conditions, mainly due to
antipsychotic treatment resistance and to relapses related to antipsychotic nonadherence. …
antipsychotic treatment resistance and to relapses related to antipsychotic nonadherence. …
Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM
…, A Prats-Galino, M Bernardo, E Parellada - Schizophrenia …, 2009 - Elsevier
Schizophrenia is a disabling illness, characterized by a heterogeneous course including
clinical deterioration and poor outcome. Accumulating findings in schizophrenia suggest that it …
clinical deterioration and poor outcome. Accumulating findings in schizophrenia suggest that it …